Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors von Ducker, G S, Atreya, C E, Simko, J P, Hom, Y K, Matli, M R, Benes, C H, Hann, B, Nakakura, E K, Bergsland, E K, Donner, D B, Settleman, J, Shokat, K M, Warren, R S

Volltext

Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates von Kelley, R.K., Nimeiri, H.S., Munster, P.N., Vergo, M.T., Huang, Y., Li, C.-M., Hwang, J., Mulcahy, M.F., Yeh, B.M., Kuhn, P., Luttgen, M.S., Grabowsky, J.A., Stucky-Marshall, L., Korn, W.M., Ko, A.H., Bergsland, E.K., Benson, A.B., Venook, A.P.

Volltext

A phase II study of axitinib in advanced neuroendocrine tumors von Strosberg, J R, Cives, M, Hwang, J, Weber, T, Nickerson, M, Atreya, C E, Venook, A, Kelley, R K, Valone, T, Morse, B, Coppola, D, Bergsland, E K

Volltext

A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer von Kelley, R K, Hwang, J, Magbanua, M J M, Watt, L, Beumer, J H, Christner, S M, Baruchel, S, Wu, B, Fong, L, Yeh, B M, Moore, A P, Ko, A H, Korn, W M, Rajpal, S, Park, J W, Tempero, M A, Venook, A P, Bergsland, E K

Volltext

Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastro... von Yao, J.C., Strosberg, J., Fazio, N., Pavel, M.E., Ruszniewski, P., Bergsland, E., Li, D., Tafuto, S., Raj, N., Campana, D., Hijioka, S., Raderer, M., Guimbaud, R., Gajate, P., Pusceddu, S., Reising, A., Degtyarev, E., Mookerjee, B., Aimone, P., Singh, S.

Volltext

Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer von Ko, A H, Hwang, J, Venook, A P, Abbruzzese, J L, Bergsland, E K, Tempero, M A

Volltext

Transcatheter pulmonic valve replacement in carcinoid heart disease von Heidecker, B, Moore, P, Bergsland, E K, Merrick, S H, Rao, R K

Volltext

The commonwealth neuroendocrine tumour collaboration (CommNETs) and North American neuroendocrine tumor society (NANETS) endorsement and update of European neuroendocrine tumor soc... von Segelov, E., Bergsland, E., Card, C., Hope, T., Kunz, P., Laidley, D., Lawrence, B., Leyden, S., Michael, M., Modahl, L., Myrehaug, S., Padda, S., Pommier, R., Ramirez, R., Soulen, M., Strosberg, J., Thawer, A., Wei, B., Singh, S.

Volltext

Maximizing the Potential of Bevacizumab in Cancer Treatment von Bergsland, Emily, Dickler, Maura N.

Volltext

Molecular mechanisms underlying the development of hepatocellular carcinoma von Bergsland, Emily K

Volltext

37LBA Telotristat etiprate is effective in treating patients with carcinoid syndrome that is inadequately controlled by somatostatin analog therapy (the phase 3 TELESTAR clinical t... von Kulke, M.H, Horsch, D, Caplin, M, Anthony, L, Bergsland, E, Oberg, K, Welin, S, Warner, R, Lombard-Bohas, C, Kunz, P, Grande, E, Valle, J, Fleming, D, Lapuerta, P, Banks, P, Jackson, S, Wheeler, D, Zambrowicz, B, Sands, A, Pavel, M

Volltext

Abstract No. 137 Post-Procedure Hyponatremia in Patients Undergoing Liver Embolotherapy for Neuroendocrine Tumor Metastases von Okwelogu, N., Vakil, P., Bergsland, E., Rolon, L., Fidelman, N.

Volltext

Aggressive Surgical Management Best Serves Patients With Small Intestinal Neuroendocrine Tumors von Imhoff, L.R, Keiser, J, Bergsland, E, Nakakura, E.K

Volltext

Arterial Thromboembolic Events in Patients with Metastatic Carcinoma Treated with Chemotherapy and Bevacizumab von Scappaticci, Frank A., Skillings, Jamey R., Holden, Scott N., Gerber, Hans-Peter, Miller, Kathy, Kabbinavar, Fairooz, Bergsland, Emily, Ngai, James, Holmgren, Eric, Wang, Jiuzhou, Hurwitz, Herbert

Volltext

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors von Bergers, Gabriele, Song, Steven, Meyer-Morse, Nicole, Bergsland, Emily, Hanahan, Douglas

Volltext

Combined Analysis of Efficacy: The Addition of Bevacizumab to Fluorouracil/Leucovorin Improves Survival for Patients With Metastatic Colorectal Cancer von KABBINAVAR, Fairooz F, HAMBLETON, Julie, MASS, Robert D, HURWITZ, Herbert I, BERGSLAND, Emily, SARKAR, Somnath

Volltext

Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide von Kulke, Matthew H, O'Dorisio, Thomas, Phan, Alexandria, Bergsland, Emily, Law, Linda, Banks, Phillip, Freiman, Joel, Frazier, Kenny, Jackson, Jessica, Yao, James C, Kvols, Larry, Lapuerta, Pablo, Zambrowicz, Brian, Fleming, Douglas, Sands, Arthur

Volltext

Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice von Hanahan, D, Bergers, G, Bergsland, E

Volltext

A Primary Xenograft Model of Pancreatic Neuroendocrine Carcinoma Maintains a Neuroendocrine Tumor Gene Expression Signature von Wang, Y, Donner, D, Venook, A, Bergsland, E, Warren, R, Nakakura, E

Volltext

Phase II, Randomized Trial Comparing Bevacizumab Plus Fluorouracil (FU)/Leucovorin (LV) With FU/LV Alone in Patients With Metastatic Colorectal Cancer von KABBINAVAR, Fairooz, HURWITZ, Herbert I, FEHRENBACHER, Louis, MEROPOL, Neal J, NOVOTNY, William F, LIEBERMAN, Grazyna, GRIFFING, Susan, BERGSLAND, Emily

Volltext